Cargando…

Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants

INTRODUCTION: Live attenuated oral vaccines against rotavirus (RV) have been shown to be less efficacious in children from developing countries. Reasons for this disparity are not fully understood. We assessed the role of maternal factors including breast milk RV-specific IgA, transplacentally acqui...

Descripción completa

Detalles Bibliográficos
Autores principales: Chilengi, Roma, Simuyandi, Michelo, Beach, Lauren, Mwila, Katayi, Becker-Dreps, Sylvia, Emperador, Devy M., Velasquez, Daniel E., Bosomprah, Samuel, Jiang, Baoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790930/
https://www.ncbi.nlm.nih.gov/pubmed/26974432
http://dx.doi.org/10.1371/journal.pone.0150100
_version_ 1782421026149236736
author Chilengi, Roma
Simuyandi, Michelo
Beach, Lauren
Mwila, Katayi
Becker-Dreps, Sylvia
Emperador, Devy M.
Velasquez, Daniel E.
Bosomprah, Samuel
Jiang, Baoming
author_facet Chilengi, Roma
Simuyandi, Michelo
Beach, Lauren
Mwila, Katayi
Becker-Dreps, Sylvia
Emperador, Devy M.
Velasquez, Daniel E.
Bosomprah, Samuel
Jiang, Baoming
author_sort Chilengi, Roma
collection PubMed
description INTRODUCTION: Live attenuated oral vaccines against rotavirus (RV) have been shown to be less efficacious in children from developing countries. Reasons for this disparity are not fully understood. We assessed the role of maternal factors including breast milk RV-specific IgA, transplacentally acquired infant serum RV-specific IgG and maternal HIV status in seroconversion among Zambian infants routinely immunized with Rotarix™ (RV1). METHODS: 420 mother-child pairs were recruited at infant age 6–12 weeks in Lusaka. Clinical information and samples were collected at baseline and at one month following the second dose of RV1. Determination of breast milk RV-specific IgA and serum RV-specific IgA and IgG was done using standardized ELISA. Seroconversion was defined as a ≥ 4 fold rise in serum IgA titre from baseline to one-month post RV1 dose 2, while seropositivity of IgA was defined as serum titre ≥ 40 and antibody variables were modelled on log-base 2. Logistic regression was used to identify predictors of the odds of seroconversion. RESULTS: Baseline infant seropositivity was 25.5% (91/357). The seroconversion frequency was 60.2% (130/216). Infants who were IgA seropositive at baseline were less likely to seroconvert compared to their seronegative counterparts (P = 0.04). There was no evidence of an association between maternal HIV status and seroconversion (P = 0.25). Higher titres of breast milk rotavirus-specific IgA were associated with a lower frequency of seroconverson (Nonparametric test for trend Z = -2.84; P<0.01): a two-fold increase in breast milk RV-specific IgA titres was associated with a 22% lower odds of seroconversion (OR = 0.80; 95% CI = 0.68–0.94; P = 0.01). There was seasonal variation in baseline breast milk rotavirus-specific IgA titres, with significantly higher GMTs during the cold dry months (P = 0.01). CONCLUSION: Low immunogenicity of RV1 vaccine could be explained in part by exposure to high antibody titres in breast milk and early exposure to wild-type rotavirus infections. Potential interference of anti-RV specific IgA in breast milk and pre-vaccination serum RV specific-IgA and IgG titres with RV1 seroconversion and effectiveness requires further research.
format Online
Article
Text
id pubmed-4790930
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47909302016-03-23 Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants Chilengi, Roma Simuyandi, Michelo Beach, Lauren Mwila, Katayi Becker-Dreps, Sylvia Emperador, Devy M. Velasquez, Daniel E. Bosomprah, Samuel Jiang, Baoming PLoS One Research Article INTRODUCTION: Live attenuated oral vaccines against rotavirus (RV) have been shown to be less efficacious in children from developing countries. Reasons for this disparity are not fully understood. We assessed the role of maternal factors including breast milk RV-specific IgA, transplacentally acquired infant serum RV-specific IgG and maternal HIV status in seroconversion among Zambian infants routinely immunized with Rotarix™ (RV1). METHODS: 420 mother-child pairs were recruited at infant age 6–12 weeks in Lusaka. Clinical information and samples were collected at baseline and at one month following the second dose of RV1. Determination of breast milk RV-specific IgA and serum RV-specific IgA and IgG was done using standardized ELISA. Seroconversion was defined as a ≥ 4 fold rise in serum IgA titre from baseline to one-month post RV1 dose 2, while seropositivity of IgA was defined as serum titre ≥ 40 and antibody variables were modelled on log-base 2. Logistic regression was used to identify predictors of the odds of seroconversion. RESULTS: Baseline infant seropositivity was 25.5% (91/357). The seroconversion frequency was 60.2% (130/216). Infants who were IgA seropositive at baseline were less likely to seroconvert compared to their seronegative counterparts (P = 0.04). There was no evidence of an association between maternal HIV status and seroconversion (P = 0.25). Higher titres of breast milk rotavirus-specific IgA were associated with a lower frequency of seroconverson (Nonparametric test for trend Z = -2.84; P<0.01): a two-fold increase in breast milk RV-specific IgA titres was associated with a 22% lower odds of seroconversion (OR = 0.80; 95% CI = 0.68–0.94; P = 0.01). There was seasonal variation in baseline breast milk rotavirus-specific IgA titres, with significantly higher GMTs during the cold dry months (P = 0.01). CONCLUSION: Low immunogenicity of RV1 vaccine could be explained in part by exposure to high antibody titres in breast milk and early exposure to wild-type rotavirus infections. Potential interference of anti-RV specific IgA in breast milk and pre-vaccination serum RV specific-IgA and IgG titres with RV1 seroconversion and effectiveness requires further research. Public Library of Science 2016-03-14 /pmc/articles/PMC4790930/ /pubmed/26974432 http://dx.doi.org/10.1371/journal.pone.0150100 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Chilengi, Roma
Simuyandi, Michelo
Beach, Lauren
Mwila, Katayi
Becker-Dreps, Sylvia
Emperador, Devy M.
Velasquez, Daniel E.
Bosomprah, Samuel
Jiang, Baoming
Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants
title Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants
title_full Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants
title_fullStr Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants
title_full_unstemmed Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants
title_short Association of Maternal Immunity with Rotavirus Vaccine Immunogenicity in Zambian Infants
title_sort association of maternal immunity with rotavirus vaccine immunogenicity in zambian infants
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790930/
https://www.ncbi.nlm.nih.gov/pubmed/26974432
http://dx.doi.org/10.1371/journal.pone.0150100
work_keys_str_mv AT chilengiroma associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants
AT simuyandimichelo associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants
AT beachlauren associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants
AT mwilakatayi associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants
AT beckerdrepssylvia associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants
AT emperadordevym associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants
AT velasquezdaniele associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants
AT bosomprahsamuel associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants
AT jiangbaoming associationofmaternalimmunitywithrotavirusvaccineimmunogenicityinzambianinfants